BACTEROMIC

New standard in the fight against antibiotic resistance

ABOUT THE PROJECT

Bacteromic Ltd. is part of the Scope Fluidics Group and was established to develop the BACTEROMIC system for assessing the drug susceptibility of microorganisms.

Increasing microbial drug resistance is one of the most serious threats to global health. Bacteromic is responding to this challenge with an innovative system that enables phenotypic evaluation of the effectiveness of antibiotics used to treat respiratory, blood, urinary tract and skin infections, among others. It also has the ability to detect the mechanism of resistance.

Bacteromic is developing and delivering the most advanced antimicrobial susceptibility testing system that is revolutionizing the treatment of bacterial infections with the rapid availability of comprehensive information. At the same time, the company is focused on raising global awareness of drug resistance and increasing its commitment to combating this threat.

WHAT NEEDS DOES THE INNOVATION ADDRESS?

Antibiotic resistance is a pervasive problem and a serious threat to public health. The large number of incorrectly prescribed, overused antibiotics has led to antibiotic resistance. Although antibiotics save lives, any use of antibiotics can lead to the development of antibiotic-resistant bacteria in humans. That’s why it’s important to get an antibiogram before using an antibiotic to find out exactly which antibiotic will fight a particular infection. BACTEROMIC, with its high informativeness, offers a comprehensive antibiogram.

The Bacteromic Company aims to make it easy for every patient to access optimal and affordable treatment through faster and more accurate antimicrobial susceptibility testing.

COMPETITIVE ADVANTAGES

BACTEROMIC is the most comprehensive AST system based on microfluidic technology;

– Can be applied to isolates and positive blood cultures;

– One panel for G+ and G- bacteria; Using microfluidics, BACTEROMIC panels offer the largest information capacity on the market, allowing up to dozens of antibiotics to be placed and tested on a patient sample regardless of the type of bacteria. Thus, it does not require the creation of separate products for G+ as well as G- bacteria, both types can be tested using one BACTEROMIC Panel.

– The highest information capacity, 640 independent chambers allow the placement of all clinically relevant antibiotics;

– Evaluation of the actual minimum inhibitory concentration (MIC) over a wide range of concentrations (6 to 14)

– High throughput – up to 60 panels in a single survey.

Learn more!